BCL2 and Sepsis: Tubeimoside I (TBM) treatment reverses the significant decrease in vascular endothelial SIRT3 expression induced by sepsis, reduces oxidative stress by decreasing NOX2 and Ac-SOD2/SOD2 levels and alleviates cell apoptosis by inhibiting cleaved caspase3 and Bax/Bcl-2 (119).